Sage suggests job and pipeline cuts after FDA rejection of major depression pill – Endpoints News

by

  1. Sage suggests job and pipeline cuts after FDA rejection of major depression pill Endpoints News
  2. Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug CNBC
  3. Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder MarketWatch
  4. Why Sage Therapeutics Shares Are Sinking Monday – Sage Therapeutics (NASDAQ:SAGE) Benzinga
  5. Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Leave a Comment